Insmed (United States)

Recent papers from Insmed (United States)

1. Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE)American Journal of Respiratory and Critical Care Medicine · 2026
2. Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non‐Cystic Fibrosis BronchiectasisCPT Pharmacometrics & Systems Pharmacology · 2026
3. Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN TrialPulmonary Therapy · 2026
4. A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung DiseasePulmonary Circulation · 2026
5. A feedback loop sustaining neutrophil extracellular trap formation involves S100 proteins, histones, TLR2 and RAGE, and is restrained by albuminFrontiers in Immunology · 2026
6. B106-14 Population Pharmacokinetics Analysis of Treprostinil Using Data From Phase 1 and 2 Studies of Treprostinil Palmitil Inhalation PowderAmerican Journal of Respiratory and Critical Care Medicine · 2026
7. D92-04 Exposure-response Relationships of Brensocatib in Adult and Adolescent Patients With Non-Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine · 2026
8. C58-17 Long-Term Hospitalizations, Comorbidities and Survival in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease in Real-World Settings Using the Norstellalinq Claims DatabaseAmerican Journal of Respiratory and Critical Care Medicine · 2026
9. B107-06 Patient and Caregiver Survey of Burden of Bronchiectasis in US and EuropeAmerican Journal of Respiratory and Critical Care Medicine · 2026
10. B45-32 Effect of Brensocatib on Patient-Reported Symptoms in Patients With Non-Cystic Fibrosis Bronchiectasis: A Post Hoc Analysis of QOL-B RSS Individual Items From the ASPEN Phase 3 TrialAmerican Journal of Respiratory and Critical Care Medicine · 2026
11. A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung DiseaseClinical Therapeutics · 2026
12. The Burden of Chronic Rhinosinusitis Without Nasal Polyps: A Systematic Review of Epidemiological, Clinical, Humanistic, and Economic Evidence.2026
13. Impact of dipeptidyl peptidase I and neutrophil serine proteases on neutrophil functional responsesSHILAP Revista de lepidopterología · 2026
14. Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyThe Lancet Respiratory Medicine · 2026
15. Impact of timing of nontuberculous mycobacterial pulmonary disease antibiotic initiation on hospitalizations in JapanRespiratory Investigation · 2026
16. Preclinical evaluation of INS1201 AAV9-micro-dystrophin via CSF administration as a potential therapy for Duchenne muscular dystrophyMolecular Therapy Advances · 2026
17. Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic FunctionsClinical Pharmacokinetics · 2026
18. Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease (ARISE): A 6-Month Double-Blind, Active Comparator TrialAnnals of the American Thoracic Society · 2026
19. Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trialRespiratory Investigation · 2026
20. Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United StatesThe Clinical Respiratory Journal · 2025